Who are Anti-TNF Drug's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abrilada, Humira, etanercept or adalimumab, Infliximab-Dyyb, Etanercept + Methotrexate, infliximab, etanercept, adalimumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-tnf-drug.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Anti-TNF Drug — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-TNF Drug (Anti-TNF Drug) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor. Area: Immunology.

phase 2 TNF-alpha inhibitor TNF-alpha Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-TNF Drug (Anti-TNF Drug) — Schneider Children's Medical Center, Israel. Anti-TNF drugs block the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-TNF Drug TARGET	Anti-TNF Drug	Schneider Children's Medical Center, Israel	phase 2	TNF-alpha inhibitor	TNF-alpha
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
etanercept or adalimumab	etanercept or adalimumab	University of Glasgow	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Infliximab-Dyyb	Infliximab-Dyyb	Asan Medical Center	marketed	TNF-alpha inhibitor; monoclonal antibody	TNF-alpha (TNFα)
Etanercept + Methotrexate	Etanercept + Methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF inhibitor + DMARD combination	TNF-alpha receptor (etanercept); dihydrofolate reductase (methotrexate)
infliximab, etanercept, adalimumab	infliximab, etanercept, adalimumab	University Hospital, Strasbourg, France	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor class)

Abbott · 4 drugs in this class
Centre for Human Drug Research, Netherlands · 2 drugs in this class
Samsung Bioepis Co., Ltd. · 2 drugs in this class
Alvotech Swiss AG · 2 drugs in this class
UCB Pharma · 2 drugs in this class
Celltrion · 2 drugs in this class
AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Assistance Publique Hopitaux De Marseille · 1 drug in this class
Asan Medical Center · 1 drug in this class
Carmel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-TNF Drug — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-tnf-drug. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab